Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001140361-17-042874
Filing Date
2017-11-14
Accepted
2017-11-14 17:07:20
Documents
57
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10q.htm 10-Q 485592
2 EXHIBIT 10.1 ex10_1.htm EX-10.1 16259
3 EXHIBIT 31.1 ex31_1.htm EX-31.1 8079
4 EXHIBIT 31.2 ex31_2.htm EX-31.2 8022
5 EXHIBIT 32.1 ex32_1.htm EX-32.1 5540
  Complete submission text file 0001140361-17-042874.txt   3147352

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ast-20170930.xml EX-101.INS 409843
7 XBRL TAXONOMY EXTENSION SCHEMA ast-20170930.xsd EX-101.SCH 41303
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ast-20170930_cal.xml EX-101.CAL 51445
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ast-20170930_def.xml EX-101.DEF 168367
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ast-20170930_lab.xml EX-101.LAB 461673
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ast-20170930_pre.xml EX-101.PRE 283758
Mailing Address 6300 DUMBARTON CIRCLE FREMONT CA 94555
Business Address 6300 DUMBARTON CIRCLE FREMONT CA 94555 510-456-3805
Asterias Biotherapeutics, Inc. (Filer) CIK: 0001572552 (see all company filings)

EIN.: 461047971 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36646 | Film No.: 171202768
SIC: 2836 Biological Products, (No Diagnostic Substances)